LAMPERTICO, PIETRO

LAMPERTICO, PIETRO  

Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti  

Mostra records
Risultati 1 - 20 di 387 (tempo di esecuzione: 0.0 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro 2023 Penna ALoglio ASoffredini RAlfieri ALampertico P + Article (author) -
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022 2023 Lampertico P. + Article (author) -
A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics 2023 Maria Paola AnolliPietro Lampertico + Article (author) -
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes 2023 Pietro Lampertico + Article (author) -
HDV RNA Assays: Performance characteristics, clinical utility and challenges 2023 Pietro Lampertico + Article (author) -
Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years 2023 S. Uceda RenteriaF. CeriniP. Lampertico + Article (author) -
Stesura di progetto internazionale di screening, vaccinazione e cura contro l'epatite C - Multi-country Viral Hepatitis COMmunity Screening, Vaccination, and Care (VH-COMSAVAC): Project outline 2023 P. LamperticoC. La Vecchia + Conference Object -
Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study 2023 Matilde TopaAndrea LombardiRiccardo CacciaAlessandra BanderaAndrea GoriPietro Lampertico + Article (author) -
Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review 2023 Elisabetta DegasperiMaria Paola AnolliPietro Lampertico Article (author) -
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals 2023 Pietro LamperticoLuca Valenti + Article (author) -
Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: Is it really needed in patients with cured HCV or suppressed HBV? 2023 Pietro Lampertico + Article (author) -
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 2023 Maria Grazia RumiPietro Lampertico + Article (author) -
The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights 2023 Lampertico PCastellano G. + Article (author) -
Induced myocardial ischemia in candidates to liver transplantation without evidence of heart disease 2023 Faggiano, AndreaLampertico, PietroVicenzi, MarcoRuscica, MassimilianoCarugo, Stefano + Article (author) -
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D 2023 Lampertico P. + Article (author) -
Hepatitis Delta: Ready for primetime? 2023 Lampertico P. + Article (author) -
Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology 2023 Lampertico P + Article (author) -
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 2023 Lampertico P + Article (author) -
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta 2023 Lampertico P + Article (author) -
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection 2023 Lampertico P + Article (author) -